Skip to main content

Table 1 Patient demographic and clinical characteristics

From: Acoustic Radiation Force Impulse (ARFI) and Transient Elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients

Demographics  
  Age (y) Median (Q1; Q3) 48 (45; 51)
  Gender n (%)  
  Female 14 (30.4)
  Male 32 (69.6)
  BMI Median (Q1; Q3) 22.4 (19.8; 24.3)
  Overweight (BMI > =25) n (%) 8 (17.4)
  Chronic alcohol abuse n (%) 15 (34.1)
  Cirrhosis n (%) 6 (13)
  Child Pugh stage n 6
  A n (%) 6 (100)
  B, C, D n 0
HIV treatment  
  Protease inhibitors n (%) 28 (60.9)
  Integrase inhibitors n (%) 3 (6.5)
  Non-nucleoside RT inhibitors n (%) 8 (17.4)
  Other treatment n (%) 7 (15.2)
HCV treatment  
  None, n (%) 28 (60.9)
  Previous treatment failure n (%) 10 (21.7)
  Previous sustained virologic response n (%) 8 (17.4)
Virology  
  HCV genotype n (%)  
  1-1a-1b 24 (59)
  2-3-3a 9 (22)
  4 41b-4a 8 (19)
  ND 5 (10)
  HCV RNA > 15 IU/ml n (%) 38 (83)
  HCV RNA IU/ml (Q1; Q3) 1116144 (391800; 3680000)
  Undetectable HIV RNA n (%) 40 (87)
  CD4/mm3 (Q1; Q3) 576 (377; 833)
Liver blood test  
  Delay between ARFI and blood test days (Q1; Q3) 0 (0; 1)
  AST or ALT ≥2N n (%) 7 (15.6)
  GGT and/or ALP ≥2N n (%) 15 (33.3)
  Bilirubin ≥2N n (%) 10 (22.2)
US liver characteristics  
  Steatosis n (%) 3 (6.5)
  Cirrhosis in US n (%) 6 (13)
  US portal hypertension signs n (%) 2 (4.3)
  US hepatomegaly n (%) 14 (30.4)
  US focal liver lesion n (%) 5 (10.9)
ARFI characteristics  
  Median (Q1; Q3) (m/s) 1.29 (1.15; 1.55)
  Min; Max 0.93; 2.86
TE characteristics  
  Median (Q1; Q3) (kPa) 6.1 (4.6; 7.2)
  Min; Max 3.4; 35.3